Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:fibroblast growth factor receptor antagonist
go back to main search page
Accession:CHEBI:63457 term browser browse the term
Definition:An antagonist at the fibroblast growth factor receptor.
Synonyms:related_synonym: FGFR inhibitor;   FGFR inhibitors;   fibroblast growth factor receptor antagonists;   fibroblast growth factor receptor inhibitor;   fibroblast growth factor receptor inhibitors


show annotations for term's descendants           Sort by:
 
AZD4547 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO AZD4547 results in decreased phosphorylation of AKT1 protein CTD PMID:26853465 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Akt1s1 AKT1 substrate 1 decreases phosphorylation ISO AZD4547 results in decreased phosphorylation of AKT1S1 protein CTD PMID:26853465 NCBI chr 1:100,845,443...100,851,961
Ensembl chr 1:100,845,563...100,851,960
JBrowse link
G Frs2 fibroblast growth factor receptor substrate 2 increases phosphorylation ISO AZD4547 results in increased phosphorylation of FRS2 protein CTD PMID:26853465 NCBI chr 7:60,128,506...60,210,482
Ensembl chr 7:60,128,508...60,210,518
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta affects expression
multiple interactions
ISO AZD4547 affects the expression of MAP1LC3B protein modified form
bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form]
CTD PMID:26853465 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation ISO AZD4547 results in decreased phosphorylation of RPS6 protein CTD PMID:26853465 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression ISO AZD4547 results in decreased expression of SREBF1 protein CTD PMID:26853465 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
nintedanib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Tuba1a tubulin, alpha 1A decreases expression ISO nintedanib results in decreased expression of TUBA1A mRNA CTD PMID:27015953 NCBI chr 7:140,637,287...140,640,953
Ensembl chr 7:140,637,287...140,640,953
JBrowse link
PD173074 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of BIRC5 protein CTD PMID:27794399 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [PKI 166 co-treated with PD 173074] results in decreased expression of CCND1 protein CTD PMID:15377668 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Fgf1 fibroblast growth factor 1 multiple interactions ISO PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] CTD PMID:15709206 NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
JBrowse link
G Fgf16 fibroblast growth factor 16 multiple interactions ISO PD 173074 inhibits the reaction [FGF16 protein results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [FGF16 protein results in increased phosphorylation of MAPK3 protein] CTD PMID:24253043 NCBI chr  X:76,786,728...76,796,311
Ensembl chr  X:76,786,466...76,797,069
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 decreases activity
decreases expression
multiple interactions
ISO PD 173074 results in decreased activity of FGFR1 protein
PD 173074 results in decreased expression of FGFR1 protein
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of FGFR1 protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of FGFR1 protein]
CTD PMID:22683780 PMID:27794399 NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 decreases activity ISO PD 173074 results in decreased activity of FGFR3 protein CTD PMID:15029211 NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706
JBrowse link
G Fgfr4 fibroblast growth factor receptor 4 multiple interactions
decreases activity
ISO PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein]
PD 173074 results in decreased activity of FGFR4 protein
CTD PMID:15377668 PMID:15709206 NCBI chr17:9,990,072...10,004,339
Ensembl chr17:9,990,078...10,004,321
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
decreases expression
multiple interactions
ISO PD 173074 results in decreased phosphorylation of MAPK1 protein
PD 173074 results in decreased expression of MAPK1 protein
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]
PD 173074 inhibits the reaction [FGF16 protein results in increased phosphorylation of MAPK1 protein]
CTD PMID:15029211 PMID:24253043 PMID:25953896 PMID:27794399 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
decreases expression
multiple interactions
ISO PD 173074 results in decreased phosphorylation of MAPK3 protein
PD 173074 results in decreased expression of MAPK3 protein
PD 173074 inhibits the reaction [FGF16 protein results in increased phosphorylation of MAPK3 protein]
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein]
CTD PMID:15029211 PMID:24253043 PMID:25953896 PMID:27794399 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [arsenic trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in increased expression of PARP1 protein modified form CTD PMID:27794399 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Phlpp1 PH domain and leucine rich repeat protein phosphatase 1 multiple interactions ISO PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] CTD PMID:25953896 NCBI chr13:26,145,989...26,394,505
Ensembl chr13:26,172,243...26,394,505
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase decreases expression
multiple interactions
ISO PD 173074 results in decreased expression of RAF1 protein; PD 173074 results in decreased expression of RAF1 protein modified form
[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein modified form; arsenic trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein]
CTD PMID:27794399 NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [PKI 166 co-treated with PD 173074] results in decreased activity of RPS6KB1 protein CTD PMID:15377668 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions
decreases expression
ISO [Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of SRC protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of SRC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein modified form]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein]
PD 173074 results in decreased expression of SRC protein; PD 173074 results in decreased expression of SRC protein modified form
CTD PMID:27794399 NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
JBrowse link
G Tbx3 T-box transcription factor 3 multiple interactions ISO PD 173074 inhibits the reaction [afimoxifene results in increased expression of TBX3 protein]; PD 173074 inhibits the reaction [Estrogens results in increased expression of TBX3 protein] CTD PMID:21098263 NCBI chr12:42,479,518...42,494,588
Ensembl chr12:42,480,560...42,492,526
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]]; PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA] CTD PMID:26800359 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19773
    role 19719
      biological role 19719
        pharmacological role 18831
          antagonist 16284
            fibroblast growth factor receptor antagonist 25
              2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoic acid 0
              AZD4547 6
              BGJ-398 0
              E-3810 0
              E-3810 free base 0
              PD173074 18
              SU5402 0
              brivanib + 0
              brivanib alaninate 0
              lenvatinib 0
              lenvatinib mesylate 0
              nintedanib 1
              nintedanib esylate 0
              sodium 2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate 0
paths to the root